



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-JAM-A [6F4] Standard Size Ab03260-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format for improved compatibility with existing reagents assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: 6F4

Alternative Name(s) of Target: CD321; JAM-1; JAM1; JCAM; F11R; PAM-1; Junctional adhesion molecule A; Junctional adhesion molecule 1; Platelet F11 receptor

UniProt Accession Number of Target Protein: Q9Y624

Published Application(s): WB, ELISA, FC, IF, IHC

Published Species Reactivity: Human

Immunogen: The original antibody was generated by immunizing BALB/c mice with MCF-7 cells. The humanized version was generated by grafting CDRs of parental mouse antibody onto human framework regions.

Specificity: This antibody specifically recognizes human junctional adhesion molecule A and does not cross-react with other members of the JAM family. JAM-A is an adherens and tight junction protein expressed by endothelial and epithelial cells. It is recently identified as an antigenic protein (Ag) overexpressed in tumor cells and associated with cancer progression.

Application Notes: This antibody was used for the characterization of human junctional adhesion molecule-A (JAM-A) and study of its expression on various cancerous tissues. The binding specificity of this antibody for human JAM-A expressed on CHO cells was confirmed using flow cytometry. JAM-A expression level on cell surface was determined by immunofluorescence staining and visualized by confocal microscopy. This antibody can also be used in the determination of JAM-A protein using western blot. Immunohistochemical analysis using this antibody revealed that JAM-A is overexpressed on breast, lung and kidney tumor tissues. Injections of anti-JAM-A antibody resulted in a significant tumor growth inhibition of xenograft human tumors in vivo. Treatment with monoclonal antibody induced a decrease of the Ki67 expression and downregulated JAM-A levels. This antigen may play a role in interfering with tumor proliferation (PMID: 22886345). This antibody binds the extracellular domain of JAM-A in an ELISA (Goetsch et al, 2011).

Antibody First Published in: Goetsch et al. A novel role for junctional adhesion molecule-A in tumor

proliferation: modulation by an anti-JAM-A monoclonal antibody. Int J Cancer. 2013 Mar 15;132(6):1463-74.
[PMID:22886345](#)

Note on publication: Describes the characterization of a new target expressed on cancerous tissues using this antibody,

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.